VectorY’s Clinical Milestone and the Shift Towards Experimentally Validated Promoters

This week, the ALS community reached a significant milestone. Our partner, VectorY Therapeutics, announced the first patient has been dosed in their Phase 1/2 PIONEER-ALS clinical trial for VTx-002.

VTx-002 represents a potential paradigm shift in treating Amyotrophic Lateral Sclerosis (ALS) by targeting TDP-43 — the protein pathology found in nearly 97% of all ALS cases. At Annogen, we are proud to share that this first-in-class vectorized antibody is powered by a bespoke, human genome-based promoter identified by Annogen, underlining the value we bring to gene therapy development.

While we celebrate the clinical progress, this moment also signals a deeper shift in how the industry approaches gene therapy design.

The Fork in the Road: Logic vs. Legacy

The development of regulatory elements for the expression of gene therapies can go through various strategies.

On one side, “conservatives” remain tethered to traditional viral promoters including SV40, CMV and CBh. While familiar, these are blunt instruments; they often lack the cell-type precision and sophisticated safety profiles,  frequently face both silencing and host immune responses.

On the other spectrum, a new wave of the industry has rushed toward AI-predicted promoters. Using computational predictions for the development of regulatory elements is powerful and will remain fundamental to the future of gene expression engineering, but this is on the assumption that it has high-quality, sensitive data to train on. AI is only as powerful as the data it consumes, and in the world of genomics, that data is frequently incomplete, unsensitive, or lacks the functional context of a patient’s body. Hence, when these computational predictions are  biological reality, we know they often struggle to perform.

Sensitive, experimental data as a basis

At Annogen, we believe the way to build a therapy that stands up to clinical rigor is to start from experimental data and thorough validations. We therefore don’t provide promoters, based on reasoning; we functionally screen the full genome in high redundancy.

Using our proprietary SuRE™ platform, we digest the human genome into 6 million fragments and test each of these individually, in parallel, a hundred times each. We then take the top performing elements – promoters and enhancers – and make >100,000 combinations and again test these, from which we pick and thoroughly validate the top candidates. The resulting promoter is ensured to be tailored to a therapy’s needs for specificity, strength and persistence, which outleagues any viral promoter or AI-based prediction.

The promoter driving VectorY’s clinical-stage VTx-002 is a product of this industry-leading approach to design promoters. By choosing a tailored, experimentally-validated element over a viral or purely AI-derived promoter, VectorY has prioritized:

• Biological Precision: Ensuring expression is tuned specifically for the target environment.
• Inherent Safety: Utilizing elements native to the human genome to reduce the risk of unforeseen cellular interference.
• Clinical Reliability: Building on a foundation of functional data that has been tested and challenged long before reaching the patient.

A New Standard for Gene Therapy

The dosing of the first patient in the PIONEER-ALS trial is more than just a win for one company; it is a proof of concept for a better way of building gene therapies. It proves that when you replace “good enough” viral elements and “uncertain” digital predictions with validated biological truth, you create a more robust path to the clinic.

We congratulate the entire team at VectorY and the clinicians at the Sean M. Healey & AMG Center for ALS. We are hopeful that this will soon be available as a new effective treatment for ALS patients worldwide.

The era of tailored, safer and more effective promoters is no longer a goal: it is officially in the clinic.